Drug Profile
Research programme: small-molecule oral therapeutics - Principia Biopharma
Latest Information Update: 28 Feb 2021
Price :
$50
*
At a glance
- Originator Principia Biopharma
- Class Small molecules
- Mechanism of Action Agammaglobulinaemia tyrosine kinase inhibitors; Interleukin 17 receptor antagonists; Interleukin-17 inhibitors; Proteasome inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Autoimmune disorders; CNS disorders; Inflammation
- Discontinued Haematological malignancies
Most Recent Events
- 28 Feb 2021 No recent reports of development identified for preclinical development in Autoimmune-disorders in USA (PO)
- 28 Feb 2021 No recent reports of development identified for preclinical development in CNS-disorders in USA (PO)
- 28 Feb 2021 No recent reports of development identified for preclinical development in Inflammation in USA (PO)